Now, it is officially gauging interest from potential private equity and strategic bidders, according to a March 14 report from Bloomberg.
Deliberations are ongoing, and Novartis could still decide to keep its assets, including its dry eye medication Xiidra that did $487 million in sales in 2022.
In 2019, Novartis spun off its eyecare business Alcon, purchasing Xiidra in the same year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.